$AUPH From 2013: Dr. Glickman suggests that voclosporin offers an attractive commercial opportunity because there are a limited number of products in development for LN. “We believe voclosporin has the potential to be very useful for some of the slower acting biologics being developed for nephritis. Where there is a need for rapid remission in patients, this drug can perform that role.” The Phase 2b trial represents a binary event, he adds. “If we get the data that we believe we are going to get, the value creation will be significant. There are a number of Big Pharma companies that would like to own this renal franchise.”